Business
Hardman Research: New advanced therapies era
Hardman Research: New advanced therapies era.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \nRNS Number : 4298Q Oxford Biomedica PLC 12 September 2017 \n\nHardman Research: New advanced therapies era\nNew advanced therapies era - OXB is a specialist advanced therapy viral-vector biopharmaceutical company. It offers vector manufacturing and development services, whilst retaining proprietary drug candidates. OXB will also receive royalties on commercial therapies developed with its LentiVector® platform. The first such therapy, also the first CAR-T therapy to ever be approved, was licensed by the FDA on 30th August 2017: tisagenlecleucel (Kymriah™) is manufactured by Novartis using lentivirus vector supplied by OXB. OXB will be the first UK company to manufacture viral vector for commercial production of a licensed gene-based medicine.\nPlease click here for the full report:\nhttp://hardmanandco.com/docs/default-source/company-docs/oxford-biomedica-documents/12.09.17-new-era-for-cell-and-gene-therapies.pdf\n\n\n\n\nTo contact us: \nHardman & Co\n35 New Broad Street\nLondon\nEC2M 1NH\n\n\nContacts:\nDr Martin Hall\[email protected] \nDr Dorothea Hill\[email protected]\nDr Gregoire Pave\[email protected]\nTelephone: +44 20 7194 7622\nFollow us on Twitter @HardmanandCo\n\n\n\n\nwww.hardmanandco.com \nAbout Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.\nHardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.\nOur research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined...